newsfilter
← Latest News
Business Wire·

Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced the completion of its 51st pre-clinical study as it continues to progress its proprietary psychedeli